| Literature DB >> 31473267 |
Sharmila Dorbala1, Yukio Ando2, Sabahat Bokhari3, Angela Dispenzieri4, Rodney H Falk5, Victor A Ferrari6, Marianna Fontana7, Olivier Gheysens8, Julian D Gillmore7, Andor W J M Glaudemans9, Mazen A Hanna10, Bouke P C Hazenberg11, Arnt V Kristen12, Raymond Y Kwong5, Mathew S Maurer3, Giampaolo Merlini13, Edward J Miller14, James C Moon7, Venkatesh L Murthy15, C Cristina Quarta7, Claudio Rapezzi16, Frederick L Ruberg17, Sanjiv J Shah18, Riemer H J A Slart9, Hein J Verberne19, Jamieson M Bourque20.
Abstract
Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.Entities:
Keywords: Cardiac amyloidosis; appropriate use; diagnosis; expert consensus; multimodality
Mesh：
Year: 2019 PMID： 31473267 DOI： 10.1016/j.cardfail.2019.08.002
Source DB: PubMed Journal: J Card Fail ISSN： 1071-9164 Impact factor: 5.712